PASPORT Carcinoid Syndrome, part of the PASPORT clinical trial research program, is a clinical trial to evaluate pasireotide for the treatment of carcinoid syndrome.
Key Inclusion Criteria:
At least 18 years of age with metastatic carcinoid tumors
Inadequate control of symptoms with current somatostatin analogues
Eligible patient symptoms:
Diarrhea + Flushing
Predominately Diarrhea
Predominately Flushing
KP>=60
Key Exclusion Criteria:
Patients who have received pasireotide prior to enrollment
Patients who have received
A somatostatin analogue higher than the maximum approved dose within the last 3 months
Radiolabeled somatostatin analogue therapy within the last 3 months
Cytotoxic chemotherapy, interferon therapy, or radiotherapy within the last 4 weeks
Uncontrolled malabsorption syndrome, short bowel, or chologenic diarrhea
